SITE012-0277

SITE012 (BRA) › SITE012-0277

SITE012-0277

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2026-08-02

completed

AEs

8

Serious

0

Dropout signal

–

Adverse events

8

Grade 2 Rash — outcome: RECOVERED/RESOLVED; onset 2023-02-13 (study day 5); relationship: not assessed

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: not assessed

moderate assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: not assessed

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: NOT RELATED

mild assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: NOT RELATED

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: NOT RELATED

moderate assessed

Data queries

1

2 adverse event records for SITE012-0277 share preferred term Asthenia and onset 2026-08-17. Duplicate entry; the first record (entered 2026-08-17) is kept.

AE.duplicate[Asthenia 2026-08-17] closed